HC Wainwright Analysts Raise Earnings Estimates for SLGL

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) – Analysts at HC Wainwright increased their Q3 2026 EPS estimates for shares of Sol-Gel Technologies in a research note issued on Tuesday, October 6th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($1.54) per share for the quarter, up from their prior estimate of ($1.71). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Sol-Gel Technologies’ current full-year earnings is ($4.95) per share. HC Wainwright also issued estimates for Sol-Gel Technologies’ Q4 2026 earnings at ($1.77) EPS, Q1 2027 earnings at ($1.14) EPS, Q2 2027 earnings at ($1.08) EPS, Q4 2027 earnings at ($1.41) EPS and FY2027 earnings at ($4.92) EPS.

Other equities analysts have also recently issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Sol-Gel Technologies in a report on Tuesday, September 1st. Mizuho assumed coverage on Sol-Gel Technologies in a research report on Wednesday, June 24th. They issued an “outperform” rating and a $285.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Sol-Gel Technologies has a consensus rating of “Moderate Buy” and a consensus price target of $197.50.

Sol-Gel Technologies Trading Down 4.9%

NASDAQ SLGL opened at $71.94 on Thursday. Sol-Gel Technologies has a 1-year low of $28.81 and a 1-year high of $97.97. The company has a market capitalization of $202.15 million, a price-to-earnings ratio of -12.76 and a beta of 1.14. The stock’s 50 day moving average is $73.58 and its two-hundred day moving average is $74.35.

Sol-Gel Technologies (NASDAQ:SLGL) last posted its earnings results on Friday, August 21st. The company reported ($1.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.36) by $1.23. Sol-Gel Technologies had a negative net margin of 910.14% and a negative return on equity of 44.05%. The business had revenue of $0.59 million for the quarter, compared to analysts’ expectations of $0.07 million.

Insider Activity

In related news, major shareholder Opaleye Management Inc. purchased 35,113 shares of the stock in a transaction that occurred on Friday, August 28th. The stock was acquired at an average price of $69.32 per share, with a total value of $2,434,033.16. Following the completion of the acquisition, the insider directly owned 520,000 shares in the company, valued at approximately $36,046,400. This trade represents a 7.24% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have purchased 53,659 shares of company stock worth $3,701,674 in the last quarter. 66.51% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Sol-Gel Technologies

An institutional investor recently bought a new position in Sol-Gel Technologies stock. Navellier & Associates Inc. bought a new stake in shares of Sol-Gel Technologies Ltd. (NASDAQ:SLGL) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 5,785 shares of the company’s stock, valued at approximately $429,000. Navellier & Associates Inc. owned about 0.21% of Sol-Gel Technologies as of its most recent filing with the SEC. 26.18% of the stock is currently owned by institutional investors.

Sol-Gel Technologies Company Profile

Sol-Gel Technologies Ltd. (NASDAQ: SLGL) is an Israeli specialty pharmaceutical company focused on developing and commercializing topical dermatological treatments. The company uses proprietary silica-based microsponge technology designed to encapsulate and gradually release active pharmaceutical ingredients in the skin.

Its marketed products include TWYNEO, a topical cream combining tretinoin and benzoyl peroxide for the treatment of acne vulgaris, and EPSOLAY, a topical benzoyl peroxide cream for the treatment of inflammatory lesions associated with rosacea.